Macrophage migration inhibitory factor is an early marker of severe acute pancreatitis based on the revised Atlanta classification

摘要

Various serum markers for early identification of severe acute pancreatitis (SAP) have been studied. Serum macrophage migration inhibitory factor (MIF) was reported to be correlated with severity of acute pancreatitis (AP) based on the 1992 Atlanta classification. However, MIF has never been proven to be predictive of disease severity based on the revised Atlanta classification (RAC). The potential predictive value of MIF needs to be further validated. Consecutive patients with AP within 48?h after symptom onset and 10 healthy control volunteers were enrolled prospectively. Serum MIF levels were measured by enzyme-linked immunosorbent assay (ELISA). The predictive value of MIF, clinical scores and other serum markers were determined. Among 143 patients with AP, there were 52 (36.4%), 65 (45.5%) and 26 (18.1%) with mild, moderate and severe disease based on the RAC respectively. Compared with healthy volunteers, serum levels of MIF were significantly higher in AP patients, especially those with SAP (P??0.001). Multivariate regression analysis indicated that increased serum MIF (cut-off 2.30?ng/ml, OR?=?3.16, P?=?0.008), IL-6 (cut-off 46.8?pg/ml, OR?=?1.21, P?=?0.043), APACHE II score (cut-off 7.5, OR?=?2.57, P?=?0.011) and BISAP score (cut-off 1.5, OR?=?1.01, P?=?0.038) were independent risk factors for predicting SAP (P??0.05). By using the area under the receiver operating characteristic (ROC) curve (AUC), MIF (AUC 0.950) demonstrated more excellent discriminative power for predicting SAP than APACHE II (AUC 0.899), BISAP (AUC 0.886), and IL-6 (AUC 0.826). Serum MIF is a valuable early marker for predicting the severity of AP based on the RAC.